# Study Evaluating Gerilimzumab´s Safety/Efficacy for Patients MTX or TNFα Antagonist Failed in Rheumatoid Arthritis

> **NCT02795299** · PHASE2 · WITHDRAWN · sponsor: **Bird Rock Bio, Inc.**

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Gerilimzumab
- **DRUG:** Methotrexate
- **DRUG:** Folic Acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02795299
- **Lead sponsor:** Bird Rock Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-01
- **Primary completion:** 2019-05
- **Final completion:** 2019-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study not started due to Sponsor decision to not move forward with compound.
- **Last updated:** 2018-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02795299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02795299, "Study Evaluating Gerilimzumab´s Safety/Efficacy for Patients MTX or TNFα Antagonist Failed in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02795299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*